drugset / Trial / NCT07087795

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

NCT07087795

Phase 1 Active not recruiting 96 enrolled Novo Nordisk A/S
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.

Timeline

Start
2025-07-01
Primary completion
2026-09-12
Completion
2026-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject zalfermin Protein / enzyme biologic Subcutaneous
Background Semaglutide Peptide Subcutaneous